FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3002094328> ?p ?o ?g. }

• W3002094328 endingPage "444" @default.
• W3002094328 startingPage "435" @default.
• W3002094328 abstract "Influenza is an important public health problem and existing vaccines are not completely protective. New vaccines that protect by alternative mechanisms are needed to improve efficacy of influenza vaccines. In 2015, we did a phase 1 trial of an oral influenza vaccine, VXA-A1.1. A favourable safety profile and robust immunogenicity results in that trial supported progression of the vaccine to the current phase 2 trial. The aim of this study was to evaluate efficacy of the vaccine in a human influenza challenge model.We did a single-site, placebo-controlled and active-controlled, phase 2 study at WCCT Global, Costa Mesa, CA, USA. Eligible individuals had an initial A/California/H1N1 haemagglutination inhibition titre of less than 20 and were aged 18-49 years and in good health. Individuals were randomly assigned (2:2:1) to receive a single immunisation of either 1011 infectious units of VXA-A1.1 (a monovalent tablet vaccine) orally, a full human dose of quadrivalent inactivated influenza vaccine (IIV) via intramuscular injection, or matched placebo. Randomisation was done by computer-generated assignments with block size of five. An unmasked pharmacist provided the appropriate vaccines and placebos to the administrating nurse. Individuals receiving the treatments, investigators, and staff were all masked to group assignments. 90 days after immunisation, individuals without clinically significant symptoms or signs of influenza, an oral temperature of higher than 37·9°C, a positive result for respiratory viral shedding on a Biofire test, and any investigator-assessed contraindications were challenged intranasally with 0·5 mL wild-type A/CA/like(H1N1)pdm09 influenza virus. The primary outcomes were safety, which was assessed in all immunised participants through 365 days, and influenza-positive illness after viral challenge, which was assessed in individuals that received the viral challenge and the required number of assessments post viral challenge. This trial is registered with ClinicalTrials.gov, number NCT02918006.Between Aug 31, 2016, and Jan 23, 2017, 374 individuals were assessed for eligibility, of whom 179 were randomly assigned to receive either VXA-A1.1 (n=71 [one individual did not provide a diary card, thus the solicited events were assessed in 70 individuals]), IIV (n=72), or placebo (n=36). Between Dec 2, 2016, and April 26, 2017, 143 eligible individuals (58 in the VXA-A1.1 group, 54 in the IIV group, and 31 in the placebo group) were challenged with influenza virus. VXA-A1.1 was well tolerated with no serious or medically significant adverse events. The most prevalent solicited adverse events for each of the treatment groups after immunisation were headache in the VXA-A1.1 (in five [7%] of 70 participants) and placebo (in seven [19%] of 36 participants) groups and tenderness at injection site in the IIV group (in 19 [26%] of 72 participants) Influenza-positive illness after challenge was detected in 17 (29%) of 58 individuals in the VXA-A1.1 group, 19 (35%) of 54 in the IIV group, and 15 (48%) of 31 in the placebo group.Orally administered VXA-A1.1 was well tolerated and generated protective immunity against virus shedding, similar to a licensed intramuscular IIV. These results represent a major step forward in developing a safe and effective oral influenza vaccine.Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, and Biomedical Advanced Research and Development Authority." @default.
• W3002094328 created "2020-01-30" @default.
• W3002094328 creator A5018857037 @default.
• W3002094328 creator A5027414840 @default.
• W3002094328 creator A5043239796 @default.
• W3002094328 creator A5044400776 @default.
• W3002094328 creator A5048548518 @default.
• W3002094328 creator A5049344401 @default.
• W3002094328 creator A5062778557 @default.
• W3002094328 creator A5070141424 @default.
• W3002094328 creator A5082570951 @default.
• W3002094328 date "2020-04-01" @default.
• W3002094328 modified "2023-10-16" @default.
• W3002094328 title "Efficacy, immunogenicity, and safety of an oral influenza vaccine: a placebo-controlled and active-controlled phase 2 human challenge study" @default.
• W3002094328 cites W1618733816 @default.
• W3002094328 cites W1895663386 @default.
• W3002094328 cites W1965570141 @default.
• W3002094328 cites W1969471820 @default.
• W3002094328 cites W1994815114 @default.
• W3002094328 cites W2012839093 @default.
• W3002094328 cites W2022615852 @default.
• W3002094328 cites W2060566204 @default.
• W3002094328 cites W2082309080 @default.
• W3002094328 cites W2161109919 @default.
• W3002094328 cites W2170155793 @default.
• W3002094328 cites W2223575612 @default.
• W3002094328 cites W2229518952 @default.
• W3002094328 cites W2616719177 @default.
• W3002094328 cites W2911964244 @default.
• W3002094328 doi "https://doi.org/10.1016/s1473-3099(19)30584-5" @default.
• W3002094328 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31978354" @default.
• W3002094328 hasPublicationYear "2020" @default.
• W3002094328 type Work @default.
• W3002094328 sameAs 3002094328 @default.
• W3002094328 citedByCount "72" @default.
• W3002094328 countsByYear W30020943282020 @default.
• W3002094328 countsByYear W30020943282021 @default.
• W3002094328 countsByYear W30020943282022 @default.
• W3002094328 countsByYear W30020943282023 @default.
• W3002094328 crossrefType "journal-article" @default.
• W3002094328 hasAuthorship W3002094328A5018857037 @default.
• W3002094328 hasAuthorship W3002094328A5027414840 @default.
• W3002094328 hasAuthorship W3002094328A5043239796 @default.
• W3002094328 hasAuthorship W3002094328A5044400776 @default.
• W3002094328 hasAuthorship W3002094328A5048548518 @default.
• W3002094328 hasAuthorship W3002094328A5049344401 @default.
• W3002094328 hasAuthorship W3002094328A5062778557 @default.
• W3002094328 hasAuthorship W3002094328A5070141424 @default.
• W3002094328 hasAuthorship W3002094328A5082570951 @default.
• W3002094328 hasConcept C126322002 @default.
• W3002094328 hasConcept C133239900 @default.
• W3002094328 hasConcept C142724271 @default.
• W3002094328 hasConcept C159047783 @default.
• W3002094328 hasConcept C159654299 @default.
• W3002094328 hasConcept C168563851 @default.
• W3002094328 hasConcept C203014093 @default.
• W3002094328 hasConcept C204787440 @default.
• W3002094328 hasConcept C22070199 @default.
• W3002094328 hasConcept C27081682 @default.
• W3002094328 hasConcept C2776291583 @default.
• W3002094328 hasConcept C2780689484 @default.
• W3002094328 hasConcept C2780868878 @default.
• W3002094328 hasConcept C71924100 @default.
• W3002094328 hasConceptScore W3002094328C126322002 @default.
• W3002094328 hasConceptScore W3002094328C133239900 @default.
• W3002094328 hasConceptScore W3002094328C142724271 @default.
• W3002094328 hasConceptScore W3002094328C159047783 @default.
• W3002094328 hasConceptScore W3002094328C159654299 @default.
• W3002094328 hasConceptScore W3002094328C168563851 @default.
• W3002094328 hasConceptScore W3002094328C203014093 @default.
• W3002094328 hasConceptScore W3002094328C204787440 @default.
• W3002094328 hasConceptScore W3002094328C22070199 @default.
• W3002094328 hasConceptScore W3002094328C27081682 @default.
• W3002094328 hasConceptScore W3002094328C2776291583 @default.
• W3002094328 hasConceptScore W3002094328C2780689484 @default.
• W3002094328 hasConceptScore W3002094328C2780868878 @default.
• W3002094328 hasConceptScore W3002094328C71924100 @default.
• W3002094328 hasIssue "4" @default.
• W3002094328 hasLocation W30020943281 @default.
• W3002094328 hasLocation W30020943282 @default.
• W3002094328 hasOpenAccess W3002094328 @default.
• W3002094328 hasPrimaryLocation W30020943281 @default.
• W3002094328 hasRelatedWork W1121313025 @default.
• W3002094328 hasRelatedWork W2019414446 @default.
• W3002094328 hasRelatedWork W2029074520 @default.
• W3002094328 hasRelatedWork W2059980695 @default.
• W3002094328 hasRelatedWork W2125247276 @default.
• W3002094328 hasRelatedWork W2158991840 @default.
• W3002094328 hasRelatedWork W2466910529 @default.
• W3002094328 hasRelatedWork W2548557566 @default.
• W3002094328 hasRelatedWork W2580111520 @default.
• W3002094328 hasRelatedWork W3091977579 @default.
• W3002094328 hasVolume "20" @default.
• W3002094328 isParatext "false" @default.
• W3002094328 isRetracted "false" @default.
• W3002094328 magId "3002094328" @default.
• W3002094328 workType "article" @default.